EMA vs Telomerase Inhibitor for RS+ patients after ESA failure

Opinion
Video

  • With the advent of new options for treatment after ESAs for patients with LR-MDS, please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the RS positive patient?

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
3 experts are featured in this series.
COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
3 experts are featured in this series.
Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
1 expert is featured in this series.
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
3 experts are featured in this series.
Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
3 experts are featured in this series.
Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
Related Content
TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

Jordyn Sava
April 22nd 2025
Article

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with stage IV colorectal cancer.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

CT-95 Phase 1 Trial Enrolls and Doses First Patient With MSLN+ Advanced Cancer

CT-95 Phase 1 Trial Enrolls and Doses First Patient With MSLN+ Advanced Cancer

Jordyn Sava
April 10th 2025
Article

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors.

Read More

Phase 1/2 Trial of TTX-MC138 Doses First Patient in Cohort 4

Phase 1/2 Trial of TTX-MC138 Doses First Patient in Cohort 4

Jordyn Sava
March 31st 2025
Article

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

Read More

Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

Jordyn Sava
March 16th 2025
Article

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.

Read More

Evofosfamide Trial Targets Hypoxia in Resistant Solid Tumors

Evofosfamide Trial Targets Hypoxia in Resistant Solid Tumors

Jordyn Sava
March 10th 2025
Article

The first patient was dosed in a phase 1/2 trial of evofosfamide with checkpoint inhibitors for hypoxia-reversal in resistant solid tumors.

Read More